Treatment of Early Age Mania

早期躁狂症的治疗

• 批准号: 6547886
• 负责人: DAVID A AXELSON
• 金额: $ 42.29万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-24 至 2004-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6547886
• 关键词: adolescence (12-20); antidepressants; behavioral /social science research tag; bipolar depression; bipolar depression manic phase; chlorpromazine; clinical research; combination therapy; cooperative study; disease /disorder onset; human subject; human therapy evaluation; mental disorder chemotherapy; middle childhood (6-11); patient oriented research; psychopharmacology; therapy compliance

DESCRIPTION (provided by applicant): This proposal was developed in collaboration with NIMH Program staff and approved for submission by Council at its 1/18/01 meeting. The two aims are:(1) To investigate the effectiveness of medications for children and adolescents who have BP-1 (manic or mixed phase) or mania. (2) To pilot a complex, multistrata, adaptive strategy design. Based on the novelty of the design and on the need for a large (and therefore costly) sample size, the applicants were asked to submit a protocol for only the first two years of the five year plan. If the first two years are successfully implemented, funding for the additional three years will be sought. For the sake of clarity, the proposal is written for the entire five years, even though the budget is limited to the first two years. Thus, the research plan provides for examining 540 subjects ages 6.0-14.11 who have DSM BP-1 (manic or mixed phase) or mania. The structure of this collaborative R01 is one coordinating site and six data collection sites. The coordinating site, for data management and analyses and for training is Washington University, St. Louis, PI: Barbara Geller, M.D. The six sites for data collection are: (1) George Washington University, Washington, D.C.., PI: Paramjit Joshi, M.D. (2) Johns Hopkins Medical Instituitions, Baltimore, PI: John walkup, M.D. (3) University of Pittsburgh, Western Psychiatric Institute and Clinic, PI: David Axelson, M.D. (4) University of Texas, Dallas, PI: Graham Emslie, M.D. (5) University of Texas, Galveston, PI: Karen Dineen Wagner, M.D. and (6) Washington University, St. Louis, PI; Joan Luby, M.D.

描述（由申请人提供）：该提案是与NIMH项目工作人员合作制定的，并由理事会在1/18/01会议上批准提交。两个目的是：(1)调查药物治疗患有BP-1（躁狂或混合期）或躁狂的儿童和青少年的有效性。(2)进行复杂、多层次、自适应的策略设计试点。基于设计的新颖性和对大量样本（因此成本高昂）的需求，申请人被要求仅提交五年计划的前两年的协议。如果头两年成功执行，将为另外三年寻求资金。